ABOUT ABBV-744 AS A POTENTIAL THERAPEUTIC OPTION FOR AGGRESSIVE CANCERS

These side effects had been notably milder in comparison with an inhibitor of both of those bromodomains. An in depth molecular Examination also disclosed that ABBV-744 preferentially inhibits the expression of Androgen Receptor (AR)-dependent genes.  ― Stephen Taylor88 These preclinical studies offer paradigms for foreseeable future clinical tr